Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)

Ivermectin study #4 of 113 Meta Analysis

7/8 Late treatment study

Gorial et al., medRxiv, doi:10.1101/2020.07.07.20145979 (Preprint)
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)

Source PDF Share Tweet

Small trial of hospitalized patients with 16 of 87 patients being treated with ivermectin showing a significantly lower mean hospital stay with ivermectin: 7.62 vs. 13.22 days, p=0.00005.

0 of 16 ivermectin patients died vs. 2 of 71 control patients.

Gorial et al., 7/8/2020, retrospective, Iraq, Middle East, preprint, 9 authors, dosage 200μg/kg single dose.

risk of death, 71.0% lower, RR 0.29, p = 1.00, treatment 0 of 16 (0.0%), control 2 of 71 (2.8%), continuity correction due to zero event (with reciprocal of the contrasting arm).

hospitalization time, 42.0% lower, relative time 0.58, p < 0.001, treatment 16, control 71.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 113 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit